Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
763.140.1%
QQQ
716.510.03%
BTC/USD
78176.900.1338%
DIA
524.880.15%
GLD
402.810.13%
TLT
81.680.06%

Bright Minds Biosciences Inc

DRUGNASDAQ
Trade with Public
Trade with Public
$65.06
-1.85-2.76%
At close: Sep 9, 5:00 PM EST
$65.06
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Bright Minds Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bright Minds Biosciences (DRUG).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

8Buy
Consensus RatingBuy# Analysts8Avg. Consensus PT$128Upside to Avg. PT+97.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$145
Aug 17, 2026BTIGThomas ShraderMaintainedBuy$147
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Bright Minds Biosciences, Raises Price Target to $220

Piper Sandler analyst Yasmeen Rahimi maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Overweight and raises the price target from $190 to $220.
Benzinga Newsdesk

PRO
Jefferies Initiates Coverage On Bright Minds Biosciences with Buy Rating, Announces Price Target of $145

Jefferies analyst Andrew Tsai initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Buy rating and announces Price Target of $145.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved